SCHEMBL6538656

SCHEMBL6538656

C=CCCCN(CCC(=O)OCC)C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 1/20 0.39
HDAC6 Q9UBN7 2/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 1/20 0.35
NR1I2 O75469 1/20 0.35
PGR P06401 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
PTGS2 P35354 1/20 0.35
PDE4D Q08499 1/20 0.35
CYP1A2 P05177 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
TSHR P16473 2/20 0.33
CYP3A4 P08684 1/20 0.33
ALOX15 P16050 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
CTSK P43235 1/20 0.32
ALOX5 P09917 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6538686 0.92 HDAC6 (0.37) CA14HDAC6ALDH1A1LMNANR1I2
SCHEMBL1272960 0.87 CA14 (0.49) CA14HDAC6ALDH1A1LMNANR1I2
SCHEMBL1440925 0.85 ALDH1A1 (0.38) CA14HDAC6ALDH1A1LMNANR1I2
SCHEMBL6538907 0.83 CA14 (0.46) CA14HDAC6CYP1A2HDAC1HDAC2
SCHEMBL29285429 0.83 CA14 (0.47) CA14HDAC6ALDH1A1NR1I2PGR
SCHEMBL7106444 0.82 CA14 (0.42) CA14HDAC6LMNANR1I2PGR
SCHEMBL20045144 0.82 CA14 (0.39) CA14HDAC6ALDH1A1LMNACYP1A2
SCHEMBL14639322 0.80 HDAC6 (0.35) CA14HDAC6ALDH1A1CYP1A2HDAC1
SCHEMBL4686524 0.79 CA14 (0.42) CA14HDAC6ALDH1A1LMNAHDAC1
SCHEMBL15312506 0.79 SMN1; SMN2 (0.38) CA14HDAC6ALDH1A1LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812235-B2 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-02 US disclosed
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ASTELLAS PHARMA INC. (JP) 2003-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ARRB1, ADRB1, GLRB CA14 1446/4885HDAC6 3137/4885ALDH1A1 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.